http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 17 Aug 2026 06:59:01 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Bioventus+Inc+%28BVS%29+PT+Raised+to+%2419+at+Canaccord/26934614.html Canaccord analyst Caitlin Cronin raised the price target on Bioventus Inc (NASDAQ: BVS) to $19.00 (from $15.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Bioventus+Inc+%28BVS%29+PT+Raised+to+%2419+at+Canaccord/26934614.html Mon, 17 Aug 2026 06:59:01 -0400 BVS http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Bioventus+Inc.++++++++++++For%3A+Jun+27/26870377.html si-local-file:///var/storage/secattach/20260805/26870377.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Bioventus+Inc.++++++++++++For%3A+Jun+27/26870377.html Wed, 05 Aug 2026 07:43:00 -0400 BVS O.30836334 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Bioventus+Inc.++++++++++++For%3A+Jun+27/26870377.html si-local-file:///var/storage/secattach/20260805/26870377.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Bioventus+Inc.++++++++++++For%3A+Jun+27/26870377.html Wed, 05 Aug 2026 07:43:00 -0400 BVS O.30836334 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Bioventus+Inc.++++++++++++For%3A+Aug+05/26870368.html si-local-file:///var/storage/secattach/20260805/26870368.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Bioventus+Inc.++++++++++++For%3A+Aug+05/26870368.html Wed, 05 Aug 2026 07:40:00 -0400 BVS O.30836334 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Bioventus+Inc.++++++++++++For%3A+Aug+05/26870368.html si-local-file:///var/storage/secattach/20260805/26870368.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Bioventus+Inc.++++++++++++For%3A+Aug+05/26870368.html Wed, 05 Aug 2026 07:40:00 -0400 BVS O.30836334 http://www.streetinsider.com/Press+Releases/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html <ul type="disc"><li><strong>Q2</strong><strong> reported revenue of $153.2 million increased 4%</strong></li><li><strong>Q2</strong><strong> GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share</strong></li><li><strong>Non-GAAP earnings* of $0.22 per diluted share compared to $0.21 per diluted share in the prior-year period</strong></li><li><strong>Cash from operations totaled $19.9 million</strong></li><li><strong>Company reaffirms revenue, Adjusted Diluted EPS* and cash from operations guidance for the full year 2026</strong></li><li><strong>Company initiates review of strategic alternatives<br/><br/></strong></li></ul> <p>DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for http://www.streetinsider.com/Press+Releases/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html Wed, 05 Aug 2026 07:30:00 -0400 A.02846591 A.14757992 BVS O.06166724 O.30836334 O.50752819 http://www.streetinsider.com/Press+Releases/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html <ul type="disc"><li><strong>Q2</strong><strong> reported revenue of $153.2 million increased 4%</strong></li><li><strong>Q2</strong><strong> GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share</strong></li><li><strong>Non-GAAP earnings* of $0.22 per diluted share compared to $0.21 per diluted share in the prior-year period</strong></li><li><strong>Cash from operations totaled $19.9 million</strong></li><li><strong>Company reaffirms revenue, Adjusted Diluted EPS* and cash from operations guidance for the full year 2026</strong></li><li><strong>Company initiates review of strategic alternatives<br/><br/></strong></li></ul> <p>DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for http://www.streetinsider.com/Press+Releases/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html Wed, 05 Aug 2026 07:30:00 -0400 A.02846591 A.14757992 BVS O.06166724 O.30836334 O.50752819 http://www.streetinsider.com/Press+Releases/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html <ul type="disc"><li><strong>Q2</strong><strong> reported revenue of $153.2 million increased 4%</strong></li><li><strong>Q2</strong><strong> GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share</strong></li><li><strong>Non-GAAP earnings* of $0.22 per diluted share compared to $0.21 per diluted share in the prior-year period</strong></li><li><strong>Cash from operations totaled $19.9 million</strong></li><li><strong>Company reaffirms revenue, Adjusted Diluted EPS* and cash from operations guidance for the full year 2026</strong></li><li><strong>Company initiates review of strategic alternatives<br/><br/></strong></li></ul> <p>DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for http://www.streetinsider.com/Press+Releases/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html Wed, 05 Aug 2026 07:30:00 -0400 A.02846591 A.14757992 BVS O.06166724 O.30836334 O.50752819 http://www.streetinsider.com/Press+Releases/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html <ul type="disc"><li><strong>Q2</strong><strong> reported revenue of $153.2 million increased 4%</strong></li><li><strong>Q2</strong><strong> GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share</strong></li><li><strong>Non-GAAP earnings* of $0.22 per diluted share compared to $0.21 per diluted share in the prior-year period</strong></li><li><strong>Cash from operations totaled $19.9 million</strong></li><li><strong>Company reaffirms revenue, Adjusted Diluted EPS* and cash from operations guidance for the full year 2026</strong></li><li><strong>Company initiates review of strategic alternatives<br/><br/></strong></li></ul> <p>DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for http://www.streetinsider.com/Press+Releases/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html Wed, 05 Aug 2026 07:30:00 -0400 A.02846591 A.14757992 BVS O.06166724 O.30836334 O.50752819 http://www.streetinsider.com/Press+Releases/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html <ul type="disc"><li><strong>Q2</strong><strong> reported revenue of $153.2 million increased 4%</strong></li><li><strong>Q2</strong><strong> GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share</strong></li><li><strong>Non-GAAP earnings* of $0.22 per diluted share compared to $0.21 per diluted share in the prior-year period</strong></li><li><strong>Cash from operations totaled $19.9 million</strong></li><li><strong>Company reaffirms revenue, Adjusted Diluted EPS* and cash from operations guidance for the full year 2026</strong></li><li><strong>Company initiates review of strategic alternatives<br/><br/></strong></li></ul> <p>DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for http://www.streetinsider.com/Press+Releases/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html Wed, 05 Aug 2026 07:30:00 -0400 A.02846591 A.14757992 BVS O.06166724 O.30836334 O.50752819 http://www.streetinsider.com/Press+Releases/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html <ul type="disc"><li><strong>Q2</strong><strong> reported revenue of $153.2 million increased 4%</strong></li><li><strong>Q2</strong><strong> GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share</strong></li><li><strong>Non-GAAP earnings* of $0.22 per diluted share compared to $0.21 per diluted share in the prior-year period</strong></li><li><strong>Cash from operations totaled $19.9 million</strong></li><li><strong>Company reaffirms revenue, Adjusted Diluted EPS* and cash from operations guidance for the full year 2026</strong></li><li><strong>Company initiates review of strategic alternatives<br/><br/></strong></li></ul> <p>DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for http://www.streetinsider.com/Press+Releases/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html Wed, 05 Aug 2026 07:30:00 -0400 A.02846591 A.14757992 BVS O.06166724 O.30836334 O.50752819 http://www.streetinsider.com/Globe+Newswire/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html <ul type="disc"><li><strong>Q2</strong><strong> reported revenue of $153.2 million increased 4%</strong></li><li><strong>Q2</strong><strong> GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share</strong></li><li><strong>Non-GAAP earnings* of $0.22 per diluted share compared to $0.21 per diluted share in the prior-year period</strong></li><li><strong>Cash from operations totaled $19.9 million</strong></li><li><strong>Company reaffirms revenue, Adjusted Diluted EPS* and cash from operations guidance for the full year 2026</strong></li><li><strong>Company initiates review of strategic alternatives<br/><br/></strong></li></ul> <p>DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for http://www.streetinsider.com/Globe+Newswire/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html Wed, 05 Aug 2026 07:30:00 -0400 A.02846591 A.14757992 BVS O.06166724 O.30836334 O.50752819 http://www.streetinsider.com/Globe+Newswire/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html <ul type="disc"><li><strong>Q2</strong><strong> reported revenue of $153.2 million increased 4%</strong></li><li><strong>Q2</strong><strong> GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share</strong></li><li><strong>Non-GAAP earnings* of $0.22 per diluted share compared to $0.21 per diluted share in the prior-year period</strong></li><li><strong>Cash from operations totaled $19.9 million</strong></li><li><strong>Company reaffirms revenue, Adjusted Diluted EPS* and cash from operations guidance for the full year 2026</strong></li><li><strong>Company initiates review of strategic alternatives<br/><br/></strong></li></ul> <p>DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for http://www.streetinsider.com/Globe+Newswire/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html Wed, 05 Aug 2026 07:30:00 -0400 A.02846591 A.14757992 BVS O.06166724 O.30836334 O.50752819 http://www.streetinsider.com/Globe+Newswire/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html <ul type="disc"><li><strong>Q2</strong><strong> reported revenue of $153.2 million increased 4%</strong></li><li><strong>Q2</strong><strong> GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share</strong></li><li><strong>Non-GAAP earnings* of $0.22 per diluted share compared to $0.21 per diluted share in the prior-year period</strong></li><li><strong>Cash from operations totaled $19.9 million</strong></li><li><strong>Company reaffirms revenue, Adjusted Diluted EPS* and cash from operations guidance for the full year 2026</strong></li><li><strong>Company initiates review of strategic alternatives<br/><br/></strong></li></ul> <p>DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for http://www.streetinsider.com/Globe+Newswire/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html Wed, 05 Aug 2026 07:30:00 -0400 A.02846591 A.14757992 BVS O.06166724 O.30836334 O.50752819 http://www.streetinsider.com/Globe+Newswire/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html <ul type="disc"><li><strong>Q2</strong><strong> reported revenue of $153.2 million increased 4%</strong></li><li><strong>Q2</strong><strong> GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share</strong></li><li><strong>Non-GAAP earnings* of $0.22 per diluted share compared to $0.21 per diluted share in the prior-year period</strong></li><li><strong>Cash from operations totaled $19.9 million</strong></li><li><strong>Company reaffirms revenue, Adjusted Diluted EPS* and cash from operations guidance for the full year 2026</strong></li><li><strong>Company initiates review of strategic alternatives<br/><br/></strong></li></ul> <p>DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for http://www.streetinsider.com/Globe+Newswire/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html Wed, 05 Aug 2026 07:30:00 -0400 A.02846591 A.14757992 BVS O.06166724 O.30836334 O.50752819 http://www.streetinsider.com/Globe+Newswire/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html <ul type="disc"><li><strong>Q2</strong><strong> reported revenue of $153.2 million increased 4%</strong></li><li><strong>Q2</strong><strong> GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share</strong></li><li><strong>Non-GAAP earnings* of $0.22 per diluted share compared to $0.21 per diluted share in the prior-year period</strong></li><li><strong>Cash from operations totaled $19.9 million</strong></li><li><strong>Company reaffirms revenue, Adjusted Diluted EPS* and cash from operations guidance for the full year 2026</strong></li><li><strong>Company initiates review of strategic alternatives<br/><br/></strong></li></ul> <p>DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for http://www.streetinsider.com/Globe+Newswire/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html Wed, 05 Aug 2026 07:30:00 -0400 A.02846591 A.14757992 BVS O.06166724 O.30836334 O.50752819 http://www.streetinsider.com/Globe+Newswire/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html <ul type="disc"><li><strong>Q2</strong><strong> reported revenue of $153.2 million increased 4%</strong></li><li><strong>Q2</strong><strong> GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share</strong></li><li><strong>Non-GAAP earnings* of $0.22 per diluted share compared to $0.21 per diluted share in the prior-year period</strong></li><li><strong>Cash from operations totaled $19.9 million</strong></li><li><strong>Company reaffirms revenue, Adjusted Diluted EPS* and cash from operations guidance for the full year 2026</strong></li><li><strong>Company initiates review of strategic alternatives<br/><br/></strong></li></ul> <p>DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for http://www.streetinsider.com/Globe+Newswire/Bioventus+Reports+Second+Quarter+Financial+Results/26870308.html Wed, 05 Aug 2026 07:30:00 -0400 A.02846591 A.14757992 BVS O.06166724 O.30836334 O.50752819 http://www.streetinsider.com/Press+Releases/Bioventus+to+Report+Second+Quarter+of+Fiscal+Year+2026+Financial+Results+on+August+5%2C+2026/26831181.html <p>DURHAM, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e0KirRdBLUdKfGoNsL-B3lQ5mGhasKYk7OPYjNqRZOTdvp3NWMlo68wRIyQIhp5jajrYVsUWYSTPiJyUk_B85dIOJlkehMVUCJA_gPUYf0rxfuWq9nKlV90ygFdxJUKC3TVN_gEDefzQB_Rk6JKdW1hus5hbNbcUwrOHHvCzEEY=" rel="nofollow" target="_blank">Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”),</a> a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market opens on Wednesday, August 5, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.</p> <p>To participate in the conference call, dial 1-800-715-9871 and refer to the Bioventus Inc. Conference Call or the Conference http://www.streetinsider.com/Press+Releases/Bioventus+to+Report+Second+Quarter+of+Fiscal+Year+2026+Financial+Results+on+August+5%2C+2026/26831181.html Wed, 29 Jul 2026 08:30:00 -0400 BVS O.30836334 http://www.streetinsider.com/Press+Releases/Bioventus+to+Report+Second+Quarter+of+Fiscal+Year+2026+Financial+Results+on+August+5%2C+2026/26831181.html <p>DURHAM, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e0KirRdBLUdKfGoNsL-B3lQ5mGhasKYk7OPYjNqRZOTdvp3NWMlo68wRIyQIhp5jajrYVsUWYSTPiJyUk_B85dIOJlkehMVUCJA_gPUYf0rxfuWq9nKlV90ygFdxJUKC3TVN_gEDefzQB_Rk6JKdW1hus5hbNbcUwrOHHvCzEEY=" rel="nofollow" target="_blank">Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”),</a> a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market opens on Wednesday, August 5, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.</p> <p>To participate in the conference call, dial 1-800-715-9871 and refer to the Bioventus Inc. Conference Call or the Conference http://www.streetinsider.com/Press+Releases/Bioventus+to+Report+Second+Quarter+of+Fiscal+Year+2026+Financial+Results+on+August+5%2C+2026/26831181.html Wed, 29 Jul 2026 08:30:00 -0400 BVS O.30836334 http://www.streetinsider.com/Globe+Newswire/Bioventus+to+Report+Second+Quarter+of+Fiscal+Year+2026+Financial+Results+on+August+5%2C+2026/26831181.html <p>DURHAM, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e0KirRdBLUdKfGoNsL-B3lQ5mGhasKYk7OPYjNqRZOTdvp3NWMlo68wRIyQIhp5jajrYVsUWYSTPiJyUk_B85dIOJlkehMVUCJA_gPUYf0rxfuWq9nKlV90ygFdxJUKC3TVN_gEDefzQB_Rk6JKdW1hus5hbNbcUwrOHHvCzEEY=" rel="nofollow" target="_blank">Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”),</a> a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market opens on Wednesday, August 5, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.</p> <p>To participate in the conference call, dial 1-800-715-9871 and refer to the Bioventus Inc. Conference Call or the Conference http://www.streetinsider.com/Globe+Newswire/Bioventus+to+Report+Second+Quarter+of+Fiscal+Year+2026+Financial+Results+on+August+5%2C+2026/26831181.html Wed, 29 Jul 2026 08:30:00 -0400 BVS O.30836334 http://www.streetinsider.com/Globe+Newswire/Bioventus+to+Report+Second+Quarter+of+Fiscal+Year+2026+Financial+Results+on+August+5%2C+2026/26831181.html <p>DURHAM, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e0KirRdBLUdKfGoNsL-B3lQ5mGhasKYk7OPYjNqRZOTdvp3NWMlo68wRIyQIhp5jajrYVsUWYSTPiJyUk_B85dIOJlkehMVUCJA_gPUYf0rxfuWq9nKlV90ygFdxJUKC3TVN_gEDefzQB_Rk6JKdW1hus5hbNbcUwrOHHvCzEEY=" rel="nofollow" target="_blank">Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”),</a> a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market opens on Wednesday, August 5, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.</p> <p>To participate in the conference call, dial 1-800-715-9871 and refer to the Bioventus Inc. Conference Call or the Conference http://www.streetinsider.com/Globe+Newswire/Bioventus+to+Report+Second+Quarter+of+Fiscal+Year+2026+Financial+Results+on+August+5%2C+2026/26831181.html Wed, 29 Jul 2026 08:30:00 -0400 BVS O.30836334 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Bioventus+Inc.+++++++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26819974.html si-local-file:///var/storage/secattach/20260727/26819974.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Bioventus+Inc.+++++++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26819974.html Mon, 27 Jul 2026 16:27:00 -0400 BVS O.30836334 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Bioventus+Inc.+++++++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26819974.html si-local-file:///var/storage/secattach/20260727/26819974.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Bioventus+Inc.+++++++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26819974.html Mon, 27 Jul 2026 16:27:00 -0400 BVS O.30836334 http://www.streetinsider.com/Options/Bioventus+%28BVS%29+14497+contracts+of+July+12.50+calls/26735197.html <p>Bioventus (NASDAQ: BVS) 30-day option implied volatility is at 68; compared to its 52-week range of 49 to 98 with a focus on 14497 contracts of July 12.50 calls. </p> http://www.streetinsider.com/Options/Bioventus+%28BVS%29+14497+contracts+of+July+12.50+calls/26735197.html Mon, 06 Jul 2026 15:40:40 -0400 BVS http://www.streetinsider.com/Investing/Bioventus+shares+rise+after+Medicare+reverses+reimbursement+cuts/26734097.html <p>Investing.com -- Bioventus Inc. shares climbed as much as 13% on Monday, reaching the highest intraday level since 2024. The increase followed an announcement that the Centers for Medicare & Medicaid Services reversed previously issued reimbursement cuts for the company's non-invasive bone growth stimulators.</p><p> </p> http://www.streetinsider.com/Investing/Bioventus+shares+rise+after+Medicare+reverses+reimbursement+cuts/26734097.html Mon, 06 Jul 2026 11:06:38 -0400 BVS